CNRMF (China Regenerative Medicine International) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNRMF China Regenerative Medicine International Ltd CNRMF
30 GF Score
Price $0.04
GF Value $0.09
! 5 Warning Signs
View Full Analysis

What is China Regenerative Medicine International Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

China Regenerative Medicine International's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

CNRMF vs VRTX, REGN, RVMD: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, China Regenerative Medicine International's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Regenerative Medicine International Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where China Regenerative Medicine International's Margin of Safety % (DCF Dividends Based) falls into.


CNRMF
30GF Score
China Regenerative Medicine International Ltd CNRMF
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Regenerative Medicine International (CNRMF) Overvalued in 2026?

Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued. The current stock price of $0.04 is trading 61.1% below its estimated GF Value™ of $0.09.

Key valuation signals for CNRMF:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $0.09 vs. price of $0.04 (61.1% below fair value)
  • GF Score™: 30/100 with 5 warning signs

No single metric tells the full story. See the CNRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Regenerative Medicine International Business Description

Other Exchanges 08158:Hong Kong
Address 132 Nathan Road, Suite 2310-2318, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score

Get the complete analysis for CNRMF

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price
$0.09
GF Value